A new inhaler for delivering anti-inflammatory medication to help manage pain in COPD patients
A Novel Aerosolization and Inhalation Platform for the Pulmonary Delivery of Anti-inflammatory Agents to Distal Airways for the Enhanced Pain Management in Chronic Obstructive Pulmonary Disease (COPD)
This study is testing a new, easy-to-use inhaler that delivers medicine directly to the deep parts of the lungs for people with COPD, aiming to help reduce inflammation and improve comfort.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scientific Horizons Consulting LLC NIH-funded |
| Lab location | 1 site (Irvine, UNITED STATES) |
| Project ID | NIH-11237357 on NIH RePORTER |
What this research studies
This research focuses on developing an innovative inhalation device designed to deliver anti-inflammatory agents directly to the deep lungs of patients with chronic obstructive pulmonary disease (COPD). The device features a unique atomizer that generates ultrafine aerosol particles, ensuring effective medication delivery to hard-to-reach areas of the lungs. It is user-friendly, requiring minimal effort to use, and includes a patented dose algorithm for personalized treatment. The goal is to improve pain management by addressing inflammation in the distal airways, which is often a source of discomfort for COPD patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with chronic obstructive pulmonary disease (COPD) who experience pain associated with lung inflammation.
Not a fit: Patients with COPD who do not experience significant pain or have contraindications to anti-inflammatory medications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly enhance pain management for COPD patients by providing more effective treatment options.
How similar studies have performed: Preliminary results from similar approaches have shown promise, indicating that targeted delivery of anti-inflammatory agents can improve patient outcomes.
Where this research is happening
Irvine, UNITED STATES
- Scientific Horizons Consulting LLC — Irvine, United States (Active)
Researchers
- Principal investigator: Gao, Xiang — Scientific Horizons Consulting LLC
- Study coordinator: Gao, Xiang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.